Jesika S. Faridi

Dr. Jesika S. Faridi

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
KSKhyati N. Shah
Khyati N. Shah
EWElizabeth A. Wilson
Elizabeth A. Wilson
RMRitu Malla
Ritu Malla
HEHoward L. Elford
Howard L. Elford
JFJesika S. Faridi
Jesika S. Faridi
Tamoxifen is widely used as an adjuvant therapy for patients with estrogen receptor (ERα)–positive tumors. However, the clinical benefit is often limited because of the emergence of drug resistance. In this study, overexpression of ribonucleotide reductase M2 (RRM2) in MCF-7 breast cancer cells resulted in a reduction in the effectiveness of tamoxifen, through downregulation of ERα66 and upregulation of the 36-kDa variant of ER (ERα36). We identified that NF-κB, HIF1α, and MAPK/JNK are the major pathways that are affected by RRM2 overexpression and result in increased NF-κB activity and increased protein levels of EGFR, HER2, IKKs, Bcl-2, RelB, and p50. RRM2-overexpressing cells also exhibited higher migratory and invasive properties. Through time-lapse microscopy and protein profiling studies of tamoxifen-treated MCF-7 and T-47D cells, we have identified that RRM2, along with other key proteins, is altered during the emergence of acquired tamoxifen resistance. Inhibition of RRM2 using siRRM2 or the ribonucleotide reductase (RR) inhibitor didox not only eradicated and effectively prevented the emergence of tamoxifen-resistant populations but also led to the reversal of many of the proteins altered during the process of acquired tamoxifen resistance. Because didox also appears to be a potent inhibitor of NF-κB activation, combining didox with tamoxifen treatment cooperatively reverses ER-α alterations and inhibits NF-κB activation. Finally, inhibition of RRM2 by didox reversed tamoxifen-resistant in vivo tumor growth and decreased in vitro migratory and invasive properties, revealing a beneficial effect of combination therapy that includes RRM2 inhibition to delay or abrogate tamoxifen resistance. Mol Cancer Ther; 14(11); 2411–21. ©2015 AACR.

1 March 2014 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
KSKhyati N. Shah
Khyati N. Shah
KMKshama R. Mehta
Kshama R. Mehta
DPDavid Peterson
David Peterson
MEMarie Evangelista
Marie Evangelista
JLJohn C. Livesey
John C. Livesey
JFJesika S. Faridi
Jesika S. Faridi
Acquired tamoxifen resistance develops in the majority of hormone-responsive breast cancers and frequently involves overexpression of the PI3K/AKT axis. Here, breast cancer cells with elevated endogenous AKT or overexpression of activated AKT exhibited tamoxifen-stimulated cell proliferation and enhanced cell motility. To gain mechanistic insight on AKT-induced endocrine resistance, gene expression profiling was performed to determine the transcripts that are differentially expressed post-tamoxifen therapy under conditions of AKT overexpression. Consistent with the biologic outcome, many of these transcripts function in cell proliferation and cell motility networks and were quantitatively validated in a larger panel of breast cancer cells. Moreover, ribonucleotide reductase M2 (RRM2) was revealed as a key contributor to AKT-induced tamoxifen resistance. Inhibition of RRM2 by RNA interference (RNAi)–mediated approaches significantly reversed the tamoxifen-resistant cell growth, inhibited cell motility, and activated DNA damage and proapoptotic pathways. In addition, treatment of tamoxifen-resistant breast cancer cells with the small molecule RRM inhibitor didox significantly reduced in vitro and in vivo growth. Thus, AKT-expressing breast cancer cells upregulate RRM2 expression, leading to increased DNA repair and protection from tamoxifen-induced apoptosis.

1 July 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RMRitu Malla
Ritu Malla
CACharles R. Ashby
Charles R. Ashby
NNNarayanan K. Narayanan
Narayanan K. Narayanan
BNBhagavathi Narayanan
Bhagavathi Narayanan
JFJesika S. Faridi
Jesika S. Faridi
ATAmit K Tiwari
Amit K Tiwari

1 June 2016 in Cancer Letters
Verified
Journal Article
Closed access
KCKarthikeyan Chandrabose
Karthikeyan Chandrabose
RMRitu Malla
Ritu Malla
CACharles R. Ashby
Charles R. Ashby
HAHaneen Amawi
Haneen Amawi
KAKodye L. Abbott
Kodye L. Abbott
ATAmit K Tiwari
Amit K Tiwari

1 July 2015 in Biochemical Pharmacology
Verified
Journal Article
Closed access
RMRitu Malla
Ritu Malla
YWYu Wang
Yu Wang
WCWilliam K. Chan
William K. Chan
ATAmit K Tiwari
Amit K Tiwari
JFJesika S. Faridi
Jesika S. Faridi

3 February 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
EWElizabeth A. Wilson
Elizabeth A. Wilson
NSNahid Sultana
Nahid Sultana
KSKhyati N. Shah
Khyati N. Shah
HEHoward L. Elford
Howard L. Elford
JFJesika S. Faridi
Jesika S. Faridi
Doxorubicin and other anthracycline derivatives are frequently used as part of the adjuvant chemotherapy regimen for triple-negative breast cancer (TNBC). Although effective, doxorubicin is known for its off-target and toxic side effect profile, particularly with respect to the myocardium, often resulting in left ventricular (LV) dysfunction and congestive heart failure when used at cumulative doses exceeding 400 mg/m2. Previously, we have observed that the ribonucleotide reductase subunit M2 (RRM2) is significantly overexpressed in estrogen receptor (ER)–negative cells as compared with ER-positive breast cancer cells. Here, we inhibited RRM2 in ER-negative breast cancer cells as a target for therapy in this difficult-to-treat population. We observed that through the use of didox, a ribonucleotide reductase inhibitor, the reduction in RRM2 was accompanied by reduced NF-κB activity in vitro. When didox was used in combination with doxorubicin, we observed significant downregulation of NF-κB proteins accompanied by reduced TNBC cell proliferation. As well, we observed that protein levels of mutant p53 were significantly reduced by didox or combination therapy in vitro. Xenograft studies showed that combination therapy was found to be synergistic in vivo, resulting in a significantly reduced tumor volume as compared with doxorubicin monotherapy. In addition, the use of didox was also found to ameliorate the toxic myocardial effects of doxorubicin in vivo as measured by heart mass, LV diameter, and serum troponin T levels. The data present a novel and promising approach for the treatment of TNBC that merits further clinical evaluation in humans.